ATE169906T1 - Verfahren zur herstellung von leukotriene- antagonisten - Google Patents

Verfahren zur herstellung von leukotriene- antagonisten

Info

Publication number
ATE169906T1
ATE169906T1 AT95906106T AT95906106T ATE169906T1 AT E169906 T1 ATE169906 T1 AT E169906T1 AT 95906106 T AT95906106 T AT 95906106T AT 95906106 T AT95906106 T AT 95906106T AT E169906 T1 ATE169906 T1 AT E169906T1
Authority
AT
Austria
Prior art keywords
compound
formula
leukotriene antagonists
het
producing
Prior art date
Application number
AT95906106T
Other languages
English (en)
Inventor
Mahadevan Bhupathy
James M Mcnamara
Daniel R Sidler
Ralph P Volante
James J Bergan
Hsien-Hsin Tung
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26870681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE169906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE169906T1 publication Critical patent/ATE169906T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/53—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
AT95906106T 1993-12-28 1994-12-22 Verfahren zur herstellung von leukotriene- antagonisten ATE169906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17493193A 1993-12-28 1993-12-28
US35042894A 1994-12-09 1994-12-09

Publications (1)

Publication Number Publication Date
ATE169906T1 true ATE169906T1 (de) 1998-09-15

Family

ID=26870681

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95906106T ATE169906T1 (de) 1993-12-28 1994-12-22 Verfahren zur herstellung von leukotriene- antagonisten

Country Status (28)

Country Link
US (2) US5614632A (de)
EP (1) EP0737186B1 (de)
JP (1) JP3640962B2 (de)
KR (1) KR100319336B1 (de)
CN (3) CN101081834B (de)
AT (1) ATE169906T1 (de)
AU (1) AU686303B2 (de)
BG (1) BG62850B1 (de)
BR (1) BR9408452A (de)
CA (1) CA2179407C (de)
CY (1) CY2104B1 (de)
CZ (1) CZ286079B6 (de)
DE (1) DE69412644T2 (de)
DK (1) DK0737186T3 (de)
ES (1) ES2122534T3 (de)
FI (1) FI113045B (de)
GE (1) GEP20012387B (de)
HR (1) HRP941022B1 (de)
HU (1) HU226394B1 (de)
LV (1) LV12313B (de)
NZ (1) NZ278263A (de)
PL (1) PL178671B1 (de)
RO (1) RO119018B1 (de)
RU (2) RU2140909C1 (de)
TW (2) TW416948B (de)
UA (1) UA44724C2 (de)
WO (1) WO1995018107A1 (de)
YU (1) YU49412B (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US20030216571A1 (en) * 1999-12-28 2003-11-20 Yoshiaki Kuroki Tricyclic compounds
EP1474386B1 (de) * 2002-02-06 2006-12-27 Delmar Chemicals Inc. Verfahren zur herstellung von 1-(mercaptomethyl)cyclopropan essigsäure
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
CA2522053C (en) * 2003-04-15 2010-06-29 Merck & Co., Inc. Polymorphic form of montelukast sodium
EP1619190B1 (de) * 2003-04-25 2010-12-29 Nippon Chemiphar Co., Ltd. Salze von (2s,3s)-3- [[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl] oxirane-2-carbonsäure
WO2004108679A1 (en) * 2003-06-06 2004-12-16 Morepen Laboratories Limited An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
IL174758A (en) 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
EP1708708A1 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-freie säure-polymorphen
EP1760077A1 (de) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Polymorphe Formen vonMontelukast freie Säure
US20050187244A1 (en) * 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
EP1711166A1 (de) 2004-02-03 2006-10-18 Chemagis Ltd. Stabile amorphe formen von montelukast natrium
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
CA2563776A1 (en) * 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
ATE539061T1 (de) * 2004-07-19 2012-01-15 Matrix Lab Ltd 2-ä(3s)-ä3-ä(2e)-(7-chlorchinolin-2- yl)ethenylüphenylü-3- halogenpropylübenzoesäuremethylester
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
WO2006021974A1 (en) * 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US20080146809A1 (en) * 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
US20080214822A1 (en) * 2004-11-30 2008-09-04 Medichem, S.A. Process For the Preparation of a Leukotriene Antagonist
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
WO2007012075A2 (en) * 2005-07-20 2007-01-25 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
EP1783117A1 (de) * 2005-11-04 2007-05-09 Esteve Quimica, S.A. Verfahren zur Herstellung eines Leukotrienantagonisten und dessen Zwischenprodukte
WO2007059325A2 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
ES2403067T3 (es) * 2005-12-13 2013-05-13 Msn Laboratories Limited Un procedimiento mejorado para la preparación de montelukast y sus sales farmaceúticamente aceptables
WO2007072114A1 (en) * 2005-12-23 2007-06-28 Glade Organics Private Limited An improved process for the manufacture of montelukast sodium
PL1976522T5 (pl) 2005-12-30 2019-12-31 Krka Tovarna Zdravil, D.D., Novo Mesto Kompozycja farmaceutyczna zawierająca montelukast
US7572930B2 (en) * 2006-02-02 2009-08-11 Chemagis Ltd. Process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
JP2009529495A (ja) * 2006-02-21 2009-08-20 ケマジス・リミテッド モンテルカストアンモニウム塩の新規な多形体およびその調製方法
WO2007096889A2 (en) * 2006-02-27 2007-08-30 Chemagis Ltd. Process for preparing montelukast and salts thereof
EP1996552A1 (de) 2006-03-17 2008-12-03 Synthon B.V. Montelukast-amantadin-salz
US20090281323A1 (en) * 2006-04-12 2009-11-12 Glade Organics Private Limited Process for the manufacture of montelukast sodium
US20090326232A1 (en) * 2006-06-26 2009-12-31 Uttam Kumar Ray Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
GB0614485D0 (en) * 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
EP2069307A4 (de) * 2006-08-04 2010-03-03 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen daraus
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
US20100081688A1 (en) * 2006-09-15 2010-04-01 Cipla Limited Process for the preparation of montelukast, and intermediates therefor
GB0618703D0 (en) * 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
WO2008058118A2 (en) * 2006-11-06 2008-05-15 Dr. Reddy's Labortories, Ltd. Preparation of montelukast and its salts
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
KR100774088B1 (ko) * 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
EP1958936A1 (de) * 2007-02-14 2008-08-20 Inke, S.A. Verfahren zur Gewinnung von Montelukast
WO2008126075A1 (en) * 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
WO2008135966A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Process for the purification of optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxy-propyl)phenyl-2-propanol
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
EP2014633A1 (de) 2007-07-13 2009-01-14 Lonza Ag Verfahren zur Herstellung tertiärer Alkohole
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
WO2009027990A1 (en) * 2007-08-29 2009-03-05 Morepen Laboratories Limited Salts of montelukast and process therefor
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
CA2701723A1 (en) * 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
EP2053043A1 (de) 2007-10-26 2009-04-29 Inke, S.A. Montelukast-Kristallsalz
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
EP2231613B1 (de) * 2008-01-07 2011-10-12 Torrent Pharmaceuticals Ltd. Montelukast-benzhydryl-piperazin-salze und verfahren zu ihrer herstellung
CN101817818B (zh) * 2008-03-06 2011-10-26 台耀化学股份有限公司 一种用于制备孟鲁司特钠的化合物
CN101323589B (zh) * 2008-03-06 2010-10-06 台耀化学股份有限公司 化合物及孟鲁司特钠的制备方法
WO2009117381A2 (en) * 2008-03-17 2009-09-24 Dr. Reddy's Laboratories Ltd. Preparation of montelukast and its salts
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
US9004752B2 (en) * 2008-05-05 2015-04-14 Abbvie, Inc. Method for evaluating the solubility of a crystalline substance in a polymer
WO2009144742A2 (en) 2008-05-26 2009-12-03 Aptuit Laurus Pvt Limited An improved process for preparing montelukast and salts thereof
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (en) 2008-12-02 2010-06-10 Mayuka Labs Private Limited An improved process for the preparation of montelukast sodium and its intermediates
WO2010148209A2 (en) * 2009-06-19 2010-12-23 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (de) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Effiziente Synthese zur Herstellung von Montelukast
CN101638381B (zh) 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 孟鲁司特钠中间体的合成方法
WO2011033470A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Crystalline form of montelukast sodium
WO2011042416A1 (en) * 2009-10-09 2011-04-14 Dsm Ip Assets B.V. Sythesis of optically active intermediate for the preparation of montelukast
US20120259121A1 (en) 2009-12-23 2012-10-11 Pharmathen S.A. Process for the preparation of montelukast and salts thereof
EP2552892A1 (de) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (de) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphersulfonsalz eines Montelukastschlüssels Zwischenprodukt
CN102633683B (zh) * 2012-04-06 2014-05-21 盐城市晶华化工有限公司 一种1-羟甲基环丙基乙腈合成方法
ES2710312T3 (es) * 2012-05-18 2019-04-24 Laurus Labs Ltd Un procedimiento para la preparación de montelukast sódico
CN103539714A (zh) * 2012-07-16 2014-01-29 上海朴颐化学科技有限公司 1-巯甲基环丙基乙酸及其中间体的制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
WO2014118796A1 (en) * 2013-01-31 2014-08-07 Melody Healthcare Pvt. Ltd. An in-situ process for the preparation of highly pure montelukast sodium
CN103570618A (zh) * 2013-09-30 2014-02-12 浙江车头制药股份有限公司 一种孟鲁司特钠盐的制备方法
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療
CN104119270A (zh) * 2014-08-12 2014-10-29 牡丹江恒远药业有限公司 一种孟鲁司特钠的制备方法
CN105085391B (zh) * 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105541786B (zh) * 2016-01-06 2017-08-08 鲁南贝特制药有限公司 一种孟鲁司特钠侧链中间体及其制备方法
CN109503476A (zh) * 2018-12-26 2019-03-22 哈尔滨珍宝制药有限公司 一种孟鲁司特钠的合成工艺
CN111170939A (zh) * 2019-12-20 2020-05-19 牡丹江恒远药业股份有限公司 一种高纯度孟鲁司特钠及其中间体的制备方法
CN117024340A (zh) * 2023-07-27 2023-11-10 迪嘉药业集团股份有限公司 一种孟鲁司特钠的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU188235B (en) * 1982-12-11 1986-03-28 Alkaloida Vegyeszeti Gyar,Hu Process for producing fluoro-methyl-quinoline derivatives
DE3483704D1 (de) * 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
HU222344B1 (hu) * 1990-10-12 2003-06-28 Merck Frosst Canada & Co. Eljárás telítetlen hidroxi-alkil-kinolinsavak, és ezeket tartalmazó gyógyszerkészítmények előállítására
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5358946A (en) * 1992-05-29 1994-10-25 The Du Pont Merck Pharmaceutical Company Heterocycle-substituted amides, carbamates and ureas as agents for the treatment of atherosclerosis
US5270234A (en) * 1992-10-30 1993-12-14 International Business Machines Corporation Deep submicron transistor fabrication method
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5371096A (en) * 1993-08-27 1994-12-06 Ciba-Geigy Corporation (3-pyridyl)tetrafuran-2-yl substituted carboxylic acids

Also Published As

Publication number Publication date
CA2179407A1 (en) 1995-07-06
HK1009269A1 (en) 1999-05-28
WO1995018107A1 (en) 1995-07-06
EP0737186A1 (de) 1996-10-16
HRP941022A2 (en) 1997-06-30
CN101081834B (zh) 2011-08-24
FI962641A0 (fi) 1996-06-26
CZ286079B6 (cs) 2000-01-12
YU77594A (sh) 1997-09-30
HRP941022B1 (en) 1999-12-31
JPH09507235A (ja) 1997-07-22
CN1046712C (zh) 1999-11-24
BR9408452A (pt) 1997-08-05
HU9601775D0 (en) 1996-09-30
JP3640962B2 (ja) 2005-04-20
RO119018B1 (ro) 2004-02-27
HUT76279A (en) 1997-07-28
YU49412B (sh) 2006-01-16
FI962641L (fi) 1996-06-26
RU2225398C2 (ru) 2004-03-10
CA2179407C (en) 2009-03-17
BG62850B1 (bg) 2000-09-29
KR100319336B1 (ko) 2002-04-22
BG100638A (bg) 1997-03-31
CN1139429A (zh) 1997-01-01
TW416948B (en) 2001-01-01
UA44724C2 (uk) 2002-03-15
GEP20012387B (en) 2001-03-25
US5614632A (en) 1997-03-25
LV12313B (en) 1999-11-20
AU686303B2 (en) 1998-02-05
DE69412644T2 (de) 1999-02-11
NZ278263A (en) 1998-04-27
TW448160B (en) 2001-08-01
PL178671B1 (pl) 2000-05-31
HU226394B1 (en) 2008-11-28
CN101081834A (zh) 2007-12-05
DK0737186T3 (da) 1999-02-08
LV12313A (lv) 1999-07-20
PL315155A1 (en) 1996-10-14
CY2104B1 (en) 2002-04-05
CN1219535A (zh) 1999-06-16
RU2140909C1 (ru) 1999-11-10
AU1444895A (en) 1995-07-17
CN1326837C (zh) 2007-07-18
DE69412644D1 (de) 1998-09-24
EP0737186B1 (de) 1998-08-19
CZ187896A3 (en) 1996-12-11
FI113045B (fi) 2004-02-27
ES2122534T3 (es) 1998-12-16
US6320052B1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
ATE169906T1 (de) Verfahren zur herstellung von leukotriene- antagonisten
ATE44954T1 (de) Carbostyrilderivat und verfahren zu seiner herstellung.
ATE206422T1 (de) Verfahren zur herstellung von aryl-piperazinyl- heterocyclischen derivaten
PT84092B (pt) Processo aperfeicoado para a preparacao de agentes anti-bacterianos de acido quinolina-3-carboxilicos
PT82381B (pt) Processo aperfeicoado para a preparacao de agentes antibacterianos de acido quinolino-3-carboxilico
ES2005746A6 (es) Un procedimiento para la preparacion de un haluro de piridinio.
SE8105102L (sv) Sett att framstella kinolinkarboxylsyraderivat
ATE29716T1 (de) Carboximid-derivate, verfahren zur herstellung und heilmittel die sie enthalten.
PT80791A (fr) Procede de preparation de nouvelles phenyl-naphtiridines utiles notamment comme medicaments anti-ulceres
YU59401A (sh) Postupak za proizvodnju alendronske kiseline
DE3866148D1 (de) Chinolincarbonsaeure-derivate, diese enthaltende zusammensetzung, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten.
DE3789409D1 (de) Verfahren zur Herstellung von Chinolin-2,3-Carbonsäure.
ATE146176T1 (de) Benzo(b)thiophen-3-yl-piperazine, verfahren zur deren herstellung und ihre verwendung als arzneimittel
KR890009926A (ko) 광학활성 벤조 퀴놀리진 화합물, 그의 제조방법 및 그것을 유효성분으로 함유하는 항세균 제제
DE3675249D1 (de) Verfahren zur herstellung von griseolinsaeurederivaten.
DE69817167D1 (de) Verfahren zur herstellung von zwischenprodukten des carbapenems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification